Gelteq Limited announced that 400,000 units of its gel solution are entering into production in November 2024. This production run is set to fulfill orders for clients in the U.S. and Australia.
Delivery of these units is expected in January 2025, targeting sales across the United States, Australia, the UAE, and Asia. The products included in this run are Gelteq nutraceuticals in the sports, anti-aging, and weight loss categories.
This volume of production so soon after the company's IPO demonstrates execution of its plans and market validation of its gel-based technology. It signifies Gelteq's ability to sell products to end-users globally and begin generating revenues in the near term.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.